Key Highlights

  • Cadrenal Therapeutics (NASDAQ:CVKD) reported a third-quarter net loss of USD 1.2 million, or USD 0.31 per share, against USD 2.7 million, or USD 1.31 per share, a year earlier.
  • General and administrative expense fell 49% to USD 1.0 million, while Research and Development dropped 67% to USD 0.2 million, as a 2025 in-process research charge did not recur.
  • Cash and cash equivalents were USD 3.1 million at September 30, 2026, down from USD 4.0 million at year-end, with an accumulated Deficit of USD 46.0 million.
  • The board launched a formal strategic review on October 7, 2026, with Tungsten Advisors weighing asset sales, partnerships or a corporate transaction.

A Sharply Lower Quarterly Loss Driven by Cost Cuts

Cadrenal Therapeutics (NASDAQ:CVKD) filed its Quarterly Report on November 16, 2026 for the period ended September 30. Operating expenses were USD 1.27 million, down 54% from USD 2.73 million, so the net loss narrowed to USD 1.25 million after USD 18,440 of interest income. The company describes itself as a late-stage biopharmaceutical Business developing therapies for immune and thrombotic conditions, with four assets: CAD-1005, tecarfarin, frunexian and CAD-2000. General and administrative costs dropped by USD 1.0 million, with USD 0.7 million tied to lower public company expenses and USD 0.3 million to lower stock-based pay. Research and development fell by USD 0.5 million, including a USD 0.2 million frunexian purchase charge booked in 2025.

Nine-Month Cash Burn and Going Concern Language

Across nine months, the net loss was USD 7.1 million versus USD 10.2 million, or USD 2.26 per share against USD 5.23. Operating Activities used USD 7.2 million, compared with USD 10.0 million a year earlier. Cash and cash equivalents of USD 3.1 million at September 30 compare with USD 4.0 million at December 31, and Working Capital was USD 2.9 million. The filing says operating losses and capital needs are expected to exceed existing cash, and it frames the situation under going concern language. Funding in 2026 included Warrant inducements, a June private Placement and sales under an at-the-market facility. Shares outstanding rose to 4,058,592 from 2,338,127 at year-end.

Strategic Review and the Funding Gap

On October 7, 2026, the board began a formal strategic review and retained Tungsten Advisors as exclusive financial advisor. The Options listed include out-licensing or selling individual Assets such as CAD-1005 or tecarfarin, partnerships with large drugmakers, and mergers or other business combinations. The company says there is no assurance that the process will produce a transaction and does not plan to give updates until a decision is made. Separately, the filing flags Nasdaq proposals that would require a minimum Market Value of listed securities of USD 5 million on the Capital Market. Management also says it lacks funding to complete its development plans and may seek grants, partnerships or additional equity.

Where Things Stand

The loss fell because costs were cut, not because the business grew. Cadrenal Therapeutics (NASDAQ:CVKD) trimmed the quarterly loss by 54%, but USD 3.1 million of cash and a flagged funding gap leave limited room. The strategic review, started on October 7, 2026, is the main way the company says it may monetize assets. Calculated from the filing, nine-month operating cash use of USD 7.2 million is more than double the cash on hand, so further financing or a transaction is the key item to watch.